Zobrazeno 1 - 10
of 21
pro vyhledávání: ''
Autor:
Richard V. Benya, Myra Arcilla, Vanessa Wong, Eva Szabo, L.M. Rodriguez, Asmita Bhattacharya, Zhiliang Huang, Rachel Gonzalez, Steven M. Lipkin, Daniel L. Gillen, Jason A. Zell, Jinah Chung, Robert Carroll, Allen Mo, Frank L. Meyskens, Chris Tucker, Timothy R. Morgan, Daniel W. Rosenberg, Wen-Pin Chen
Publikováno v:
Cancer Prevention Research. 8:222-230
Colorectal cancer progresses through multiple distinct stages that are potentially amenable to chemopreventative intervention. Epidermal growth factor receptor (EGFR) inhibitors are efficacious in advanced tumors including colorectal cancer. There is
Autor:
Matthew Meyerson, Derek Y. Chiang, Amit Dutt, Ying S. Chao, Sandra Pastorino, William D. Johnson, Robert C. Onofrio, Roel G.W. Verhaak, Jihyun Kwon, Hideo Watanabe, Yuki Yuza, Jeonghee Cho, Santosh Kesari, Andrew D. Cherniack, Xiaoyin Xu, Qing Treitler Zeng, Scott R. VandenBerg
Publikováno v:
Cancer Research. 71:7587-7596
Genomic alterations of the epidermal growth factor receptor (EGFR) gene play a crucial role in pathogenesis of glioblastoma multiforme (GBM). By systematic analysis of GBM genomic data, we have identified and characterized a novel exon 27 deletion mu
Autor:
Qian Li, Howard C. Crawford, Venkateshwar Madka, Naveena B. Janakiram, Vernon E. Steele, Stan Lightfoot, Misty Ely, Altaf Mohammed, Chinthalapally V. Rao
Publikováno v:
Cancer Prevention Research. 3:1417-1426
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy with a dismal prognosis. Developing novel strategies to prevent or delay pancreatic cancer is currently of intense interest. The chemopreventive efficacy of gefitinib, a
Autor:
Hossein Borghaei, Kathy Q. Cai, Vladimir Khazak, Mark A. Hitrik, Peter Makhov, Anna S. Nikonova, Rohan Brebion, Ilya G. Serebriiskii, Yanis Boumber, Brian L. Egleston, Eleanor Avril, Erica A. Golemis, Emmanuelle Nicolas, Alexander E. Kudinov, Alexander Y. Deneka
Publikováno v:
Cancer Research. 78:4452-4452
Musashi-2 (MSI2) is an RNA-binding protein that regulates mRNA translation. We recently established that MSI2 is elevated in a subset of non-small cell lung cancer (NSCLC) tumors upon progression and drives NSCLC metastasis, in part based on activity
Autor:
John V. Heymach, Eugene Lifshits, George N. Naumov, Tina Cascone, Daniel G. Tenen, Bruce E. Johnson, Lars A. Akslen, Jeffrey A. Engelman, Monique B. Nilsson, Hua Kang Wu, Oddbjørn Straume, Pasi A. Jänne, Beow Y. Yeap, Balazs Halmos, Xi M. Tang, Alexandra Briggs, Judah Folkman, Lauren Averett Byers, Li Xu, Susumu Kobayashi
Publikováno v:
Clinical Cancer Research. 15:3484-3494
Purpose: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) gefitinib and erlotinib benefit some non–small cell lung cancer (NSCLC) patients, but most do not respond (primary resistance) and those who initially respond eve
Autor:
Sabine Tejpar, Wendy De Roock, Diether Lambrechts, Bart Claes, Eric Van Cutsem, Hans Prenen, Bart Jacobs, Jef De Schutter, Bart Biesmans
Publikováno v:
Clinical cancer research
Purpose: It has been reported that activating KRAS mutations negatively affect response to anti–epidermal growth factor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. The mutation status of signaling molecules downstream of
Publikováno v:
Molecular Cancer Therapeutics. 14:A63-A63
N-myc downstream regulated gene-1 (NDRG1) is a potent metastasis suppressor that has been shown to affect numerous signaling pathways that control oncogenesis. In this study, the role of NDRG1 was investigated on a key upstream effector, namely epide
Autor:
Mathew S. Varghese, Edward L. Chan, Michael J. Hayman, Anjaruwee S. Nimnual, Kristen A. VanHeyst, James Keller
Publikováno v:
Cancer Research. 75:3274-3274
Background: Epidermal Growth Factor Receptor (EGFR) is a biologic target for cancer therapy. Clinical response to EGFR inhibitors is variable. Recently, EGFR mutations were found to predict response to anti-EGFR therapy. Since a few children with Neu
Autor:
Darlene B. Royce, Karen T. Liby, Ryan M. Collins, Michael B. Sporn, Renee Risingsong, Charlotte R. Williams
Publikováno v:
Cancer Research. 74:LB-245
Lung cancer and pancreatic cancer are leading causes of cancer deaths, with extremely poor 5 year survival rates for both types of cancer. The epidermal growth factor receptor (EGFR) and its ligands regulate cell growth, and EGFR expression is freque
Autor:
Ashley M. Kern, Patricia Greninger, Jason A. Efstathiou, Mechthild Krause, Henning Willers, Meng Wang, Dipanjan Chowdhury, Anurag K. Singh, Michael Baumann, Marieke Hülskötter, Yunfeng Pan, Jeff Settleman, Cyril H. Benes
Publikováno v:
Cancer Research. 74:LB-209
Non-small cell lung cancer (NSCLC) with mutations in the KRAS oncogene is generally resistant to targeted agents directed against the epidermal growth factor receptor (EGFR). Although EGFR is active in KRAS-mutant cancers its role in supporting cell